Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

COCH vs CERS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CERS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–4 Matrix Metrics)

CERS Overall Winner 6-Pillar Tally: COCH 1 – 5 CERS Matrix Metrics: COCH 4 – 5 CERS

As of Nov 20, 2026, Cerus Corp (CERS) is the stronger overall head-to-head candidate over Envoy Medical, Inc. (COCH) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). COCH carries a Unified Composite Score of 35.1/100 (SELL) at $6.70 (N/M Forward P/E, -10261.0% operating margin), whereas CERS carries 55.5/100 (HOLD) at $1.85 (123.3x Forward P/E, -1.1% operating margin).

  • Growth vs. Quality Trade-Off: CERS earns the overall head-to-head edge with a stronger Unified Composite Score (55.5/100 HOLD vs. COCH 35.1/100 SELL) and 1.51β · 76% Vol risk profile, whereas COCH leads top-line expansion (+57.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: COCH trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 77.7); meanwhile CERS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About COCH vs CERS
COCH NASDAQ
Envoy Medical, Inc. Class A Common Stock
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$6.70
+0.0% 1D
Market Cap $51.9M
TTM Revenue $231,000
Forward P/E N/M
Beta / 30D Vol 4.94β · 3352% Vol
Unified Composite Score
35.1 / 100 SELL
Tech 50.0 Fund 27.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (348.7% over 20 days), RSI 78
RSI-14: 77.7 · SMA20: $6.79 · SMA50: $3.12
CERS NASDAQ Head-to-Head Winner
Cerus Corp
Surgical & Medical Instruments & Apparatus
$1.85
-2.63% 1D
Market Cap $383.7M
TTM Revenue $227M
Forward P/E 123.3x
Beta / 30D Vol 1.51β · 76% Vol
Unified Composite Score
55.5 / 100 HOLD
Tech 60.0 Fund 64.0 Flow 66.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.7%), weak momentum, RSI 36
RSI-14: 36.0 · SMA20: $2.13 · SMA50: $2.30

6-Pillar Scorecard Institutional Category Breakdown (COCH 1 – 5 CERS)

Columns: Metric · COCH · CERS
1. Valuation Multiples CERS
Forward P/E N/M 123.3x
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 119.2x 2.0x
2. Growth & Scale CERS
Revenue Growth (YoY) +57.1% +9.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $231,000 $227M
Market Cap $51.9M $383.7M
3. Profitability & Quality CERS
Gross Margin N/A 51.8%
Operating Margin -10261.0% -1.1%
Net Profit Margin 0.0% -3.2%
Return on Equity (ROE) 0.0% -10.7%
4. Balance Sheet & Cash Flow CERS
Cash Generation (TTM) -$21M $494,000
Cash Flow Margin N/A 0.2%
Net Cash / Leverage $24M Net Cash $59M Net Debt (0.99x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning COCH
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 59.8% (32nd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat CERS
OpEx & R&D Intensity N/A 52.9% of Rev ($120M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: COCH (4) vs CERS (5)
Institutional Metric COCH CERS Criterion Row Edge
Market Capitalization
Scale
$51.9M $383.7M Larger Scale CERS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M 123.3x Lower Multiple CERS
Revenue Growth (YoY)
Growth
+57.1% +9.5% Higher Growth COCH
Operating Margin (TTM)
Profitability
-10261.0% -1.1% Higher Margin CERS
Net Profit Margin
Profitability
0.0% -3.2% Higher Margin COCH
Return on Equity (ROE)
Capital Efficiency
0.0% -10.7% Higher ROE COCH
52-Week Range Position
Momentum
89% ($0–$7) 19% ($1–$3) Stronger Trend COCH
Beta / 30D Volatility
Risk Regime
4.94β · 3352% Vol 1.51β · 76% Vol Lower Realized Risk CERS
Unified Institutional Score
Composite Signal
35.1 / 100 (SELL) 55.5 / 100 (HOLD) Higher Composite CERS
Trailing 12M Revenue (USD)
Operating Scale
$231,000 $227M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 51.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 119.2x EV/Rev N/M PEG · 2.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M ($24M Net Cash) $494,000 ($59M Net Debt (0.99x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon COCH +1044.26 pp
COCH: +1024.35% · CERS: -19.91%
3M Horizon COCH +829.11 pp
COCH: +797.88% · CERS: -31.23%
6M Horizon COCH +876.72 pp
COCH: +844.99% · CERS: -31.73%
1Y Horizon COCH +820.88 pp
COCH: +843.4% · CERS: +22.52%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period COCH Revenue CERS Revenue COCH Op. Margin CERS Op. Margin Margin Leader
FY2018 N/A $80M N/A -72.3% CERS
FY2019 N/A $90M N/A -70.6% CERS
FY2020 N/A $110M N/A -51.1% CERS
FY2021 N/A $160M N/A -30.7% CERS
FY2022 $0M $190M -3673.4% -18.1% CERS
FY2023 $0M $190M -5809.8% -16.1% CERS
FY2024 $0M $200M -8558.2% -7.1% CERS
FY2025 $0M $230M -9240.7% -3.7% CERS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
COCH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact COCH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CERS BREAKDOWN
122d in phase · OBV NEUTRAL
Current IV 59.8%
IV Percentile 32nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CERS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
COCH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $51.9M market capitalization and -10261.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CERS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $383.7M market capitalization and -1.1% operating margin.
OpEx & R&D Reinvestment 52.9% of Rev ($120M)
90D Engineering Disclosures 0 Published

Investor FAQ COCH vs CERS Key Questions & Quantitative Answers

As of Nov 20, 2026, Cerus Corp (CERS) is the stronger overall head-to-head candidate over Envoy Medical, Inc. (COCH) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). COCH carries a Unified Composite Score of 35.1/100 (SELL) at $6.70 (N/M Forward P/E, -10261.0% operating margin), whereas CERS carries 55.5/100 (HOLD) at $1.85 (123.3x Forward P/E, -1.1% operating margin). Growth vs. Quality Trade-Off: CERS earns the overall head-to-head edge with a stronger Unified Composite Score (55.5/100 HOLD vs. COCH 35.1/100 SELL) and 1.51β · 76% Vol risk profile, whereas COCH leads top-line expansion (+57.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: COCH trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 77.7); meanwhile CERS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CERS leads the Growth & Scale pillar: COCH posts +57.1% YoY revenue growth and +0.0% YoY earnings growth on $231,000 TTM revenue (N/A gross margin, -10261.0% operating margin), compared with CERS at +9.5% YoY revenue growth and +0.0% YoY earnings growth on $227M TTM revenue (51.8% gross margin, -1.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), COCH cumulative revenue shifted N/A while CERS shifted +187.5%. In operating R&D and SG&A reinvestment, COCH deploys N/A (0 90-day corporate R&D disclosures) versus 52.9% of Rev ($120M) (0 disclosures) for CERS.

CERS screens cheaper on headline valuation multiples. COCH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 119.2x EV/Revenue (unreported FCF margin), whereas CERS trades at 123.3x Forward P/E, N/M Trailing P/E, N/M PEG, and 2.0x EV/Revenue (0.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against COCH (0.0% ROE) versus CERS (-10.7% ROE) capital efficiency.

In options market volatility and institutional positioning, COCH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.94β · 3352% Vol realized risk). By comparison, CERS carries 59.8% implied volatility (32nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.51β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.